China approves drug to cure Alzheimer’s; to go on sale from next month


Team Udayavani, Nov 4, 2019, 2:29 PM IST

Beijing: In a major breakthrough, China has approved a home-grown drug to cure Alzheimer’s, the first in two decades, state media reported on Monday.

China’s National Medical Products Administration has approved the market launch of the drug, GV-971, last Saturday, state-run China Daily reported.

Patients will be able to buy the drug around China from December 29, and more production lines will gradually be put into operation to satisfy the market demand, according to Shanghai Green Valley Pharmaceutical, one of the drug’s developers.

The drug is the only Alzheimer’s medicine out of more than 320 developed by pharmaceutical companies around the globe to survive clinical trials, despite the investment of hundreds of billions of US dollars over the past two decades, the report said.

Extracted from brown algae, the orally taken drug is the world’s first multi-targeting and carbohydrate-based drug for Alzheimer’s, the administration said.

It can treat mild to moderate forms of the disease and improve cognition, it said.

The first production line for the drug, which will meet the needs of two million patients, will begin running this week.

Alzheimer’s disease, an irreversible and progressive brain disorder that slowly destroys memory, thinking ability and the capability to carry out simple tasks, affects at least 50 million people worldwide, and the number is expected to increase as populations age.

China has roughly 10 million people with Alzheimer’s, the highest in the world.

The Chinese Academy of Sciences’ Shanghai Institute of Materia Medica, which jointly developed the GV-971 with Green Valley and Ocean University of China after 22 years of research, said there were previously five medicines with limited efficacy used to treat the disease, which was discovered a century ago.

A phase III clinical trial of the drug involving 818 patients completed in July last year had “proven to continuously and effectively improve cognition among mild to moderate Alzheimer’s disease sufferers over a period of nine months,” said Geng Meiyu, lead researcher on the drug and a researcher with SIMM.

“Addiction and serious toxicity of the therapy haven’t been identified in research so far,” she said.

Scientists said the drug functions mainly by rebalancing gut microbiota, reducing neuro-inflammation and reducing cognitive impairment. Some doctors from home and abroad, including David Holtzman, chairman of the American Neurological Association, said they believe GV-971 will provide a new medical solution for patients.

Preparations are being made for the drug’s clinical trials in the US and international multi-centre research, its developers said, with initial communication with the US Food and Drug Administration already completed.

“Green Valley has established a professional team and hired world-renowned experts in this field as consultants in preparation for initiating clinical trials in the US,” said Lyu Songtao, the company’s chairman.

“We don’t exclude the possibility of collaborating with international research institutions to perform clinical trials in the US,” the Daily report quoted Lyu as saying.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Maharashtra Polls: Eknath Shinde targets Uddhav for `giving up’ Bal Thackeray’s principles for power

Will appear before Lokayukta for questioning in MUDA case, says CM Siddaramaiah

Lies have short life, Cong’s ‘fake’ narrative smashed: Fadnavis

Temple idols found desecrated in Hyderabad, case registered

SC junks plea against quashing of LOC issued to ex-house help of Sushant Singh Rajput

JPC chairman Jagdambika Pal to visit K’taka on Nov 7 to meet farmers protesting Waqf notices

Indian boxer Mandeep Jangra wins WBF’s world title

Related Articles More

Weight loss could help one manage PCOS symptoms, study suggests

Risk of abnormal blood fat levels increased by about 30 pc during pandemic, finds study

Attention problems could be ‘middleman’ between genetic risk for, experiencing psychosis: Study

Meeting WHO’s sodium recommendations could avert deaths from heart, kidney disease: Study

Meeting WHO’s sodium recommendations could avert deaths from heart, kidney disease: Study

MUST WATCH

Gho Pooja in Deepavali Festival

Melukote Deepavali

Ganapathi Co-operative Society Ltd

Udayavani Chinnara Banna 2024

Annapoorna Aahar | Food Places In Mysore


Latest Additions

Davanagere: Man murdered by relative for insurance money; 4 arrested within 24 hours

Heroin worth Rs 3.5 crore recovered in police raid in Delhi, 2 arrested

Govt clerk found dead in Tahsildar’s chamber, FIR filed against minister’s PA, 2 others

Treated Muslims like fuel for ‘lantern’: Prashant Kishor targets Lalu, asks upper castes to stay away from Nitish

MP Brijesh Chowta urges Kerala CM for strict action against attack on Edneer Swamiji’s vehicle

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.